Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | polo-like protein kinase, putative | 0.0097 | 1 | 0.5 |
Leishmania major | protein kinase, putative,polo-like protein kinase, putative | 0.0097 | 1 | 0.5 |
Onchocerca volvulus | Serine\/threonine kinase homolog | 0.0097 | 1 | 0.5 |
Loa Loa (eye worm) | PLK/PLK1 protein kinase | 0.0097 | 1 | 1 |
Echinococcus multilocularis | serine:threonine protein kinase PLK1 | 0.0097 | 1 | 1 |
Trypanosoma brucei | polo-like protein kinase | 0.0097 | 1 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0065 | 0.3302 | 0.3302 |
Trichomonas vaginalis | CAMK family protein kinase | 0.0097 | 1 | 0.5 |
Entamoeba histolytica | serine/threonine protein kinase, putative | 0.0097 | 1 | 0.5 |
Trichomonas vaginalis | CAMK family protein kinase | 0.0097 | 1 | 0.5 |
Trichomonas vaginalis | CAMK family protein kinase | 0.0097 | 1 | 0.5 |
Giardia lamblia | Kinase, PLK | 0.0097 | 1 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0065 | 0.3302 | 0.3302 |
Trichomonas vaginalis | CAMK family protein kinase | 0.0097 | 1 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0065 | 0.3302 | 0.3302 |
Trichomonas vaginalis | CAMK family protein kinase | 0.0097 | 1 | 0.5 |
Trypanosoma cruzi | polo-like protein kinase, putative | 0.0097 | 1 | 0.5 |
Trichomonas vaginalis | CAMK family protein kinase | 0.0097 | 1 | 0.5 |
Echinococcus granulosus | serine:threonine protein kinase PLK1 | 0.0097 | 1 | 1 |
Schistosoma mansoni | serine/threonine protein kinase | 0.0097 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0065 | 0.3302 | 0.3302 |
Schistosoma mansoni | tar DNA-binding protein | 0.0065 | 0.3302 | 0.3302 |
Trichomonas vaginalis | CAMK family protein kinase | 0.0097 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Inhibition (functional) | = 0 % | GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 LDH activity, using an LDH reporter assay. Test compounds present at 2uM | ChEMBL. | 20485427 |
Inhibition (functional) | = 7.35 % | ST_JUDE_LEISH: Cytotoxicity at 2uM final concentration against transgenic Leishmania Mexicana promastigotes LmPfHT that are glucose transport deficient and complemented with the Plasmodium falciparum hexose transporter. Activity is measured by by DNA content using SYBR green in vitro | ChEMBL. | No reference |
Inhibition (functional) | = 7.8 % | ST_JUDE_LEISH: Cytotoxicity at 2uM final concentration against transgenic Leishmania Mexicana promastigotes LmGLUT1 that are glucose transport deficient and complemented with the human glucose transporter GLUT1. Activity is measured by DNA content using SYBR green in vitro | ChEMBL. | No reference |
Inhibition (functional) | = 8.28 % | ST_JUDE_LEISH: Cytotoxicity at 2uM final concentration against transgenic Leishmania Mexicana promastigotes LmGT2 that are glucose transport deficient and complemented with the L. Mexicana glucose transporter 2. Activity is measured by by DNA content using SYBR green in vitro | ChEMBL. | No reference |
Inhibition (functional) | = 23 % | GSK_TCMDC: Percent inhibition of human HepG2 cell line. Test compounds present at 10uM. | ChEMBL. | 20485427 |
Inhibition (functional) | = 26 % | GSK_TCMDC: Inhibition of Plasmodium falciparum Dd2 in whole red blood cells, using parasite LDH activity as an index of growth. Test compounds present at 2uM | ChEMBL. | 20485427 |
Inhibition (functional) | = 95 % | GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 in whole red blood cells, using parasite LDH activity as an index of growth. Test compounds present at 2uM | ChEMBL. | 20485427 |
XC50 (functional) | = 0.8902 uM | GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 in whole erythrocytes, using parasite LDH activity as an index of growth. | ChEMBL. | 20485427 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.